ЯРЯ. Д. Рафальська

Я. Д. Рафальська

*This is an algorithmically generated author record based on publicly available information.

Я. Д. Рафальська has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Formation of the organizational and legal mechanism for ensuring gender equality in the pharmaceutical sector of the healthcare system of Ukraine

    by N. M. Sakhnatska, Ya. D. Rafalska

    In the context of reforming the healthcare system of Ukraine, it is particularly important to modernize gender-sensitive personnel policies, which are part of the socially responsible management paradigm. The pharmaceutical industry in Ukraine is highly feminized, but there are still barriers to protecting women’s labor rights, ensuring equal access to managerial decision-making, fair remuneration, opportunities for professional growth and a balanced distribution of working hours and rest. This determines the urgency of the problem and the need for its thorough scientific understanding. Aim. To substantiate the need to form an organizational and legal mechanism for ensuring gender equality in the pharmaceutical sector of Ukraine, taking into account the national legislation, international experience and current challenges related to the transformation of the healthcare system under martial law. Materials and methods. The research materials were normative legal acts in the field of healthcare and pharmacy, scientific publications by domestic and foreign authors, non-financial reports of leading global pharmaceutical companies, as well as information resources from the official websites of public professional associations. The following methods were used in the course of the work: the content analysis of regulatory and legal acts, scientific publications and non-financial reports, a systematic approach, a structural-logical method, methods of comparison and generalization, as well as a graphical method for visualizing the research results. Results and discussion. It has been found that despite the existence of legislative guarantees of gender equality, Ukraine lacks a systemic mechanism for implementing a gender-sensitive approach in the management of pharmaceutical organizations. The experience of leading pharmaceutical companies, including practices of gender-sensitive human resource policies, mentoring programs, and initiatives to reduce the gender pay gap, has been summarized. Based on the systematization of the data, a multi-level model for implementing gender equality principles at the macro-, meso-, and micro-levels has been proposed. Conclusions. The results of the analysis confirm the prospect of forming a comprehensive organizational and legal mechanism for ensuring gender equality as a necessary condition for the sustainable development of the pharmaceutical sector in Ukraine. The integration of the gender approach will contribute to improving the efficiency, innovation and sustainability of the industry in the context of the European integration and post-war reconstruction. The multi-level model proposed for implementing the gender policy – at the macro, meso and micro levels – is of great practical importance as it provides a comprehensive approach to eliminating gender disparities, strengthening human resources and institutional capacity of pharmaceutical organizations.


  • Open Access

    Analysis of the domestic market of vitamin D products and dietary supplements and their availability to the population

    by Л. О. Гала, Я. Д. Рафальська

    In recent decades, scientists have identified several therapeutic benefits of vitamin D for the human body. Modern diets, environmental factors, and unhealthy lifestyles are among the reasons for its deficiency. Today, more than 80% of the world's population and 90% of Ukrainians live in conditions of vitamin D deficiency. At the same time, a wide range of medicines and dietary supplements (DS) on the market allows consumers to solve the problem by preventive measures as prescribed by a doctor or on their own with the advice of a pharmacist. The purpose of the study was to analyze the marketing of vitamin D products – medicines and DS – on the Ukrainian pharmaceutical market and to determine the level of their availability and affordability to consumers. The objects of the study were regulatory documents and scientific sources on the prophylactic use of vitamin D products; the pharmaceutical market of medicines and DS of the selected group. Methods used: bibliographic, analytical-comparative, marketing analysis, graphical and generalization. According to the results of the marketing study of vitamin D products, it was found that 43 medicines are registered on the pharmaceutical market, of which only 17 are available in the assortment of pharmacies, and 140 DS are represented, i.e. the share of medicines in retail sales is 10,8% of the total number of items. Vitamin D is mainly used in the form of cholecalciferol (drugs – 82,3% and DS – 100,0%). As for the distribution by dosage forms, most often these are soft capsules and tablets. Among the countries producing medicines, Ukraine has the advantage (53,0%), and among DS – the USA (34,3%) and Ukraine (25,0%). The analysis of the availability of vitamin D products shows that 53,0% of medicines and 22,9% of DS are characterized by a high and fairly high level of availability (over 50%). The results of the price assessment of medicines and DS indicate mainly their affordability (value of additional daily tariff rate < 1), especially in case of preventive dosing (from 200 IU to 2,000 IU), as well as the affordability of more expensive offers in pharmacies depending on the country of manufacture, dosage, etc. At the same time, the issues of annual growth of the DS segment in the pharmacy assortment, gradual transfer of vitamin D medicines to the DS group, ensuring the quality and safety of DS and legislative regulation of their circulation remain problematic today.

  • Open Access

    AUTOMATION OF POLYCYSTIC OVARY SYNDROME DIAGNOSTICS THROUGH MACHINE LEARNING ALGORITHMS IN ULTRASOUND IMAGING

    by Roman Galagan, Serhiy Andreiev, Nataliia Stelmakh, Yaroslava Rafalska, Andrii Momot

    This article presents a study aimed at using machine learning to automate the analysis of ultrasound images in the diagnosis of polycystic ovary syndrome (PCOS). Today, various laboratory and instrumental methods are used to diagnose PCOS, including the analysis of ultrasound images performed by medical professionals. The peculiarity of such analysis is that it requires high qualification of medical professionals and can be subjective. The aim of this work is to develop a software module based on convolutional neural networks (CNN), which will improve the accuracy and objectivity of diagnosing polycystic disease as one of the clinical manifestations of PCOS. By using CNNs, which have proven to be effective in image processing and classification, it becomes possible to automate the analysis process and reduce the influence of the human factor on the diagnosis result. The article describes a machine learning model based on CNN architecture, which was proposed by the authors for analyzing ultrasound images in order to determine polycystic disease. In addition, the article emphasizes the importance of the interpretability of the CNN model. For this purpose, the Gradient-weighted Class Activation Mapping (Grad-CAM) visualization method was used, which allows to identify the image areas that most affect the model's decision and provides clear explanations for each individual prediction.


  • Open Access

    Analysis of pharmaceutical supply of breast cancer patients

    by Yaroslava Rafalska, Kostyantyn Kosyachenko

    The aim: to conduct a clinical and economic analysis of the state of pharmaceutical support for patients with breast cancer in women. Materials and methods. During the research, data from the National List of Essential Medicines, the 14th State Formulary of Medicines, the Ukrainian clinical protocol, the clinical protocols of Great Britain and the United States of America for the treatment of breast cancer, and a depersonalized database of drug prescriptions were used. The research used such methods as clinical-economic, organizational-economic, mathematical-statistical, graphic, grouping and generalization. Research results. It was established that 46 schemes of schemes for the treatment of breast cancer are presented in Ukrainian and international clinical protocols (Great Britain, USA). In all three protocols, there were 5 regimens for the treatment of breast cancer, such as CMF (Cyclophosphamide, Methotrexat, Fluorouracil), AC (Doxorubicin, Cyclophosphamide), DC (Docetaxel, Cyclophosphamide), TC (Trastuzumab, Capecitabin), EC (Epirubicin, Cyclophosphamide). Analysis of the pharmaceutical component in the protocols for individual drugs showed that they included 23 drugs according to the INN, which belong to the group of antineoplastic drugs. The Ukrainian clinical protocol includes 17 drugs, the British protocol – 14 drugs, and the American one – 15 drugs. The frequency analysis of antineoplastic drugs included in the Ukrainian clinical protocol revealed the TOP-3 in terms of drug prescription frequency: L01A A01 Cyclophosphamide (Ki=0.037), L01C D02 Docetaxel (Ki=0.029), L01D B01 Doxorubicin (Ki=0.026). The largest number of prescribed drugs are vital drugs – 61.96 %, the smallest share – essential drugs – 2.17 %, and the share of non-essential drugs is 35.87 %. The ABC analysis made it possible to determine the group of the most expensive drugs in the treatment of breast cancer - these are antineoplastic and immunomodulating agents. The total expenses for this group amounted to UAH 772,459.96, which according to the US dollar exchange rate of the National Bank of Ukraine at the end of August 2022 was USD 21,122.77. According to the analysis of the matrix of the integrated ABC-VEN-frequency analysis, it was established that the largest number of prescriptions belonged to the group of less expensive and vital drugs (B/V) – 7 drugs (48.73 % of the total amount. At the same time, the largest amount of expenses is observed in for the A/V group – UAH 772,459.96 (52.83 % of all costs directed to the pharmaceutical support of patients). The results of the structural analysis of the group of the most expensive drugs showed that the highest costs were characteristic of L01CD02 Docetaxel (UAH 1166,531.31; 39.81 % of the total cost in the group), and the lowest – for L01DB01 Doxorubicin – UAH 63,694.14 (5.46 %, respectively). Conclusions. According to the results of the conducted research, it was established that the largest costs fall on the group of essential drugs (1047735.07 UAH, 71.65 % of all costs). This determines the need for further pharmacoeconomic calculations of breast cancer treatment to optimize the costs of antineoplastic drugs


  • Open Access

    Analysis of the morbidity of breast cancer in Ukraine and the city of Kyiv

    by Я. Д. Рафальська, K. L. Kosyachenko

    One of the main causes of mortality worldwide is malignant neoplasms, and in Ukraine, breast cancer ranks first among all cancer diseases and mortality among women. With the help of official epidemiological data, it is possible to estimate the level and forecast the costs of the prevention and treatment of breast cancer in women. The purpose of the study was to analyze epidemiological indicators of breast cancer incidence and mortality among the female population in Ukraine and the city of Kyiv. The study used data on the incidence and mortality from breast cancer in women of the National Cancer Registry of Ukraine for 2011–2021. Analytical-comparative, epidemiological, graphic, and mathematical-statistical methods were used. The results of the analysis of epidemiological indicators showed that the largest number of sick women was registered in 2012 – 17,746, and the smallest in 2020 – 12,736. The highest growth rate of the chain coefficient of decrease/increase in the incidence and mortality rate of breast cancer in women was in 2015 – 23% and 8%, respectively. The lowest number of registered cases of breast cancer for 2016–2020 in Ukraine is observed in the Western region, and the largest in the Northern region. The highest mortality rate was recorded in women in the city of Kyiv and in Ukraine as a whole from breast cancer in 2012 (18.2 and 16.9 per 100,000 population, respectively). In general, the mortality trend in the city of Kyiv is higher than in Ukraine. The results of the analysis showed that breast cancer is most often detected for the first time at the I–II stage of the disease. The largest number of such patients was found in Ukraine in 2015 – 78.6% of the total number of cases. Taking into account the analyzed epidemiological data on the incidence and mortality of women from breast cancer in Ukraine and the city of Kyiv, it is necessary to conduct social programs for early screening of breast cancer at the state level and provide such patients with effective anticancer drugs at all stages of treatment.